24/7 Wall Street
12 Sept 2026, 19:15 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Analysis by Kasper Rasmussen · Founder & analyst
What the story claims
4 claims · each scored for market impact
Bristol Myers Squibb's Eliquis drug faces a projected revenue decline of $1.5 billion to $2 billion in 2027 and U.S. patent expiration in April 2028. — Loss of exclusivity on a major revenue driver creates a structural threat to earnings and dividend sustainability.
-0.60BMY's Growth Portfolio now accounts for nearly 60% of total revenue and grew by 14%. — Strong growth in newer products helps offset the 'patent cliff' risks of legacy drugs.
+0.40The company maintains a strong liquidity position with approximately $11.5 billion in cash and marketable securities as of Q2. — High cash reserves provide a safety net for dividends and the ability to fund pipeline development or acquisitions.
+0.30Continue reading
5 related stories
Search tags
The Legacy Portfolio (including Revlimid and Pomalyst) is currently declining at a rate of 12% to 16% due to generic competition. — Confirms an ongoing erosion of older revenue streams that must be backfilled by the pipeline.
-0.20Which stocks this story touches
While the company has strong growth in its newer portfolio and a solid dividend history, it faces a significant 'patent cliff' and revenue step-down for Eliquis.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
24/7 Wall Street
3h ago
